Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer.

Trial Profile

Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 06 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top